Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lymphoma, T-Cell, Cutaneous 2Lymphoma 2Sezary Syndrome 1Mycosis Fungoides 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms 1Breast Carcinoma In Situ 1

Interventions

Carboplatin 41Cisplatin 38Paclitaxel 34Specimen Handling 32Radiotherapy 27Magnetic Resonance Spectroscopy 25Gemcitabine 23Vinorelbine 15Etoposide 15Docetaxel 15Biopsy 13Pemetrexed 10Cyclophosphamide 10pembrolizumab 9Taxes 9Immunoglobulin G 9Disulfides 9Platinum 81,2-diaminocyclohexaneplatinum II citrate 8X-Rays 7Vinblastine 7Erlotinib Hydrochloride 7osimertinib 6durvalumab 6atezolizumab 6Nivolumab 6Irinotecan 6Ifosfamide 6Chemotherapy, Adjuvant 6Celecoxib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lung Neoplasms × Bexarotene × Clear all
NCT00514293 2014-01-10

Bexarotene, Tretinoin, and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
39 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡